Asston Pharmaceuticals Ltd544445Corporate

Latest results: Mar 2026 4 quarters of data

—

MCap —

Live price not available

Asston Pharmaceuticals Ltd — Stock analysis & AI research Asston Pharmaceuticals Ltd — Live exchange announcements

AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.

₹10 Cr

Sales · Mar 2026

+10.8% YoY

₹-3 Cr

Operating Profit · Mar 2026

-188.1% YoY

-27.9%

OPM % · Mar 2026

-179.5% YoY

₹0 Cr

Net Profit · Mar 2026

-75.4% YoY

₹0.56

EPS · Mar 2026

-82.0% YoY

📝 Asston Pharmaceuticals Ltd — results explained

Quarter ended March 2026 (Q4 FY26)

Asston Pharmaceuticals Ltd reported revenue of ₹10 crore for the quarter ended March 2026 (Q4 FY26), up 10.8% from ₹9 crore in the same quarter last year.

Net profit fell 75.4% year-on-year to ₹0 crore, from ₹2 crore. Earnings per share (EPS) came in at ₹0.56.

Operating profit stood at ₹-3 crore — an operating margin (OPM) of -27.9%, compared with 35.1% in the year-ago quarter.

Full year and trailing twelve months

On a trailing-twelve-month (TTM) basis, revenue stands at ₹25 crore with a net profit of ₹1 crore.

Shareholding pattern

As of Mar 2026, promoters held 50.66%, foreign institutional investors (FIIs) 1.91%, public shareholders 47.41% of Asston Pharmaceuticals Ltd.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close

Valuation

Market Cap ?

N/A

Current Price ?

N/A

P/E ?

N/A

Industry P/E ?

N/A

P/B ?

N/A

P/S ?

N/A

P/FCF ?

N/A

Enterprise Value ?

N/A

EV/EBITDA ?

N/A

PEG ?

N/A

Earnings Yield ?

N/A

Dividend Yield ?

0.00%

Profitability & Returns

Sales (TTM) ?

₹25 Cr

OPM ?

-2.2%

Profit after tax (TTM) ?

₹1 Cr

EPS (TTM) ?

₹0.60

ROCE ?

16.8%

ROE ?

1.3%

ROA ?

1.0%

Growth

Sales — latest qtr ?

₹10 Cr

PAT — latest qtr ?

₹0 Cr

YoY qtr sales growth ?

10.8%

YoY qtr profit growth ?

-75.4%

Sales growth (3y) ?

57%

Sales growth (5y) ?

N/A

Profit growth (3y) ?

54%

Profit growth (5y) ?

N/A

Financial Health

Debt ?

₹5 Cr

Debt to Equity ?

0.13

Interest Coverage ?

N/A

Current Ratio ?

N/A

Ownership

Promoter holding ?

50.66%

Change in promoter holding ?

0.00%

Pledged percentage ?

N/A

Market

Return 3 months ?

N/A

Return 6 months ?

N/A

🗓️ Quarterly results (4 quarters · ₹ Cr)

same fiscal quarter as Mar bestweakest per row · for costs (interest, NPAs) low is best Highlight

Metric	Sep 2024	Mar 2025	Sep 2025	Mar 2026	YoY %	QoQ %
Sales	16	9	15	10	+10.8%	—
Operating Profit	2	3	2	-3	-188.1%	—
Other Income	1	-0	-2	5	+6714.3%	—
Interest	0	1	0	0	-32.1%	—
Depreciation	0	0	0	0	+1150.0%	—
Profit Before Tax	2	3	0	1	-52.3%	—
Net Profit	2	2	0	0	-75.4%	—
EPS	24.24	3.11	0.04	0.56	-82.0%	—
OPM %	14.2%	35.1%	14.5%	-27.9%	-179.5%	—

📆 Annual results (₹ Cr, FY = Apr–Mar)

Annual rollup not yet available We need at least 3 quarters of a fiscal year to compute annual figures. This symbol does not yet have a complete fiscal year in our database.

🏛️ Balance Sheet (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Equity Capital	0.70	0.78	6.27	8.51	+35.7%
Reserves	1.29	6.40	4.76	30.35	+537.6%
Borrowings	5.24	6.82	7.25	5.11	-29.5%
Other Liabilities	6.46	6.70	9.84	7.68	-22.0%
Total Liabilities	13.69	20.70	28.12	51.65	+83.7%
Fixed Assets	1.13	0.97	0.96	10.69	+1013.5%
CWIP	0.00	0.00	0.00	0.00	—
Investments	0.00	0.00	0.00	0.00	—
Other Assets	12.56	19.73	27.16	40.96	+50.8%
Total Assets	13.69	20.70	28.12	51.65	+83.7%

💧 Cash Flow (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Cash from Operating Activity	-0.32	-3.97	-0.03	-10.18	-33833.3%
Cash from Investing Activity	-0.91	-0.01	0.73	-9.91	-1457.5%
Cash from Financing Activity	1.21	3.86	-0.51	21.18	+4252.9%
Net Cash Flow	-0.01	-0.12	0.19	1.09	+473.7%
Free Cash Flow	-0.57	-3.98	-0.06	-20.24	-33633.3%
CFO/OP	-20%	-92%	-0%	1,368%	—

➗ Ratios (latest 4 periods)

Metric	Mar 2023	Mar 2024	Mar 2025	Mar 2026	% Chg
Debtor Days	480.53	380.71	357.86	524.07	+46.4%
Inventory Days	204.29	53.91	18.59	16.14	-13.2%
Days Payable	754.51	217.50	154.11	120.76	-21.6%
Cash Conversion Cycle	-69.70	217.12	222.34	419.45	+88.7%
Working Capital Days	43.53	162.80	178.86	434.22	+142.8%
ROCE %	37.14%	37.78%	36.62%	16.80%	-54.1%

👥 Shareholding (latest 2 periods)

Metric	Sep 2025	Mar 2026	% Chg
Promoters	50.66%	50.66%	+0.0%
FIIs	6.04%	1.91%	-68.4%
Public	43.30%	47.41%	+9.5%
No. of Shareholders	751	687	-8.5%

⚖️ Peer comparison

Peer comparison unavailablePeer comparison unavailable — industry and sector are not classified for this symbol.

❓ Frequently asked questions

What was Asston Pharmaceuticals Ltd's revenue in Q4 FY26?